西酞普兰治疗功能性胃肠病伴焦虑抑郁障碍的临床观察

摘要

目的：观察西酞普兰治疗伴焦虑抑郁障碍功能性胃肠病（FGIDS）的临床疗效及安全性。方法：将62例伴焦虑抑郁障碍FGIDS患者按随机数字表法分为治疗组（34例）和对照组（28例）。对照组患者给予常规治疗，治疗组患者在常规治疗基础上加服西酞普兰片10 mg，qd（起始剂量，根据患者症状逐步加量至40 mg，qd）。两组患者疗程均为3个月。比较两组患者治疗前后消化道症状积分、汉密尔顿抑郁量表（HAMD）及汉密尔顿焦虑量表（HAMA）评分、临床疗效及不良反应发生情况。结果：两组患者治疗前消化道症状积分、HAMD及HAMA评分比较，差异无统计学意义（P＞0.05）；治疗后，两组患者上述评分均显著降低，且治疗组明显低于对照组，差异均有统计学意义（P＜0.05）。治疗组患者临床总有效率显著高于对照组（94.12％vs.67.86％），差异有统计学意义（P＜0.05）。仅治疗组患者4例出现轻微的不良反应。结论：西酞普兰治疗伴焦虑抑郁障碍FGIDS疗效显著，能有效改善患者消化道症状及焦虑、抑郁状态，且安全性较好。%OBJECTIVE:To observe the clinical efficacy and safety of citalopram in the treatment of functional gastrointesti-nal disorders complicated with anxiety or depression. METHODS:62 patients with functional gastrointestinal disorders complicat-ed with anxiety or depression were randomly divided into treatment group(34 cases)and control group(28 cases). Control group was given routine treatment,treatment group was additionally given Citalopram tablet with initial dose of 10 mg,qd,increasing to 40 mg qd,according to the situation of patients,on the basis of control group. Treatment course of 2 groups lasted for 3 months. The gastrointestinal symptom integral,HAMD and HAMA were compared between 2 groups before and after treatment,and clini-cal efficacy and the occurrence of ADR were observed. RESULTS:There was no statistical significance in gastrointestinal symptom integral,HAMD and HAMA between 2 groups before treatment (P>0.05). After Treatment,above scores of 2 groups decreased significantly,and the treatment group was lower than the control group,with statistical significance(P<0.05). Total effective rate of treatment group was significantly higher than that of control group (94.12% vs. 67.86%),with statistical significance (P<0.05). Olny 4 patients of treatment group suffered from mild ADR. CONCLUSIONS:Citalopram shows significant therapeutic effi-cacy in the treatment of functional gastrointestinal disorders complicated with anxiety or depression,and can improve digestive tract symptom and anxiety or depression,and help to improve patients’gastrointeseinal symptoms with good safety.